Japanese Patent Grants for IMP321 in Cancer
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 05/01/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office.
This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .
Mr Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel-MAGNUS
+61 2 8234 0100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2016 - 00:00 Uhr
Sprache: Deutsch
News-ID 467759
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 307 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Japanese Patent Grants for IMP321 in Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
